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Introduction:  Sinistral,  or  left-sided,  portal  hypertension  (SPH)  is  a  rare  entity,  with  multiple
potential causes.  Gastrointestinal  variceal  bleeding  and  hypersplenism  are  its’  major  clinical
manifestations.  The  main  aim  of  the  present  study  is  to  summarize  the  clinical  features  of
patients with  SPH.
Patients  and  methods:  This  was  a  retrospective  analysis  of  consecutive  patients  with  present
or previous  diagnosis  of  SHP,  observed  in  a  Gastroenterology  Department,  in  a  period  of  2
years. Patients  with  clinical,  radiological  or  laboratory  alterations  suggestive  of  cirrhosis  were
excluded. Causes  of  SPH,  clinical  manifestations  and  outcomes  were  registered.  Potential  fac-
tors associated  with  gastrointestinal  bleeding  were  analyzed.
Results:  In  the  study  period  a  total  of  22  patients  (male  --  17;  mean  age  --  59.6  ±  10.6  years)
with SHP  were  included.  Clinical  manifestations  were:  asymptomatic/unspeciﬁc  abdominal
pain (n  =  14);  gastrointestinal  bleeding  (n  =  8).  Eleven  (50%)  patients  had  increased  aminotrans-
ferases, GGT  and/or  alkaline  phosphatase  although  liver  function  was  normal  in  all  of  them.
Causes of  SPH  were  chronic  pancreatitis  (n  =  7),  acute  pancreatitis  (n  =  7),  pancreatic  cancer
(n =  4),  pancreatic  surgery  (n  =  3)  and  arteriovenous  malformation  (n  =  1).  All  patients  had  gas-
tric and/or  esophageal  varices  and  seven  had  splenomegaly.  Five  (22.7%)  had  thrombocytopenia,
associated  with  hypersplenism.  Five  patients  (22.7%)  were  submitted  to  endoscopic  treatment
and eight  were  submitted  to  splenic  artery  embolization  and/or  splenectomy.  There  were  no
cases of  variceal  rebleeding  and  two  patients  died.  Patients  without  liver  enzymes  elevation
had a  higher  probability  of  gastrointestinal  bleeding  (87.5%  vs.  28.6%;  p  =  0.024).
Conclusions:  Acute  and  chronic  pancreatitis  are  the  major  causes  of  SHP.  Gastrointestinal  bleed-
ing is  the  most  important  clinical  manifestation  and  patients  without  liver  enzyme  elevation
seem more  prone  to  bleed.  Speciﬁc  treatment  is  seldom  performed  or  needed.uesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.
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Hipertensão  Portal  Esquerda:  Uma  Entidade  Sinistra
Resumo
Introduc¸ão:  A  hipertensão  portal  esquerda  ou  sinistra  (HTPS)  é  uma  entidade  rara,  que  pode
resultar de  diferentes  etiologias.  A  hemorragia  gastrointestinal  de  origem  varicosa  e  o  hipere-
splenismo são  as  principais  manifestac¸ões  clínicas.  O  principal  objetivo  do  presente  estudo
consiste em  estabelecer  os  achados  clínicos  mais  relevantes  num  grupo  de  doentes  com  HTPS.
Doentes e  métodos: Foi  efetuada  uma  análise  retrospetiva  de  um  grupo  consecutivo  de  doentes
com HTPS  diagnosticados  ou  acompanhados  no  servic¸o  de  Gastrenterologia  durante  o  período
de 2  anos.  Os  doentes  com  estigmas  clínicos,  radiológicos  ou  laboratoriais  sugestivos  de  cirrose
hepática foram  excluídos.  Foram  registadas  as  etiologias,  manifestac¸ões  clínicas,  tratamentos
e evoluc¸ão.  Também  foram  analisados  potenciais  fatores  associados  com  hemorragia  digestiva
como forma  de  apresentac¸ão.
Resultados:  Neste  período  foram  incluídos  22  doentes  (sexo  masculino  --  17;  média  etária  --
59,6 ±  10,6  anos).  As  manifestac¸ões  clínicas  foram:  assintomático/dor  abdominal  inespecíﬁca
(n =  14);  hemorragia  gastrointestinal  (n  =  8).  A  func¸ão  hepática  era  normal  em  todos  os  doentes
mas 11  (50%)  apresentavam  uma  elevac¸ão  da  enzimologia  hepática  (aminotransferases,  GGT
e/ou fosfatase  alcalina).  As  principais  etiologias  da  HTPS  foram  a  pancreatite  crónica  (n  =  7),  a
pancreatite  aguda  (n  =  7),  os  carcinomas  pancreáticos  (n  =  4),  as  cirurgias  pancreáticas  prévias
(n =  3)  e  uma  malformac¸ão  arterio-venosa  (n  =  1).  Foram  identiﬁcadas  varizes  gástricas  e/ou
esofágicas  em  todos  os  doentes  e  7  apresentavam  esplenomegália.  A  trombocitopenia,  associada
ao hiperesplenismo,  estava  presente  em  5  doentes  (22,7%).  Cinco  doentes  foram  submetidos  a
tratamento  endoscópico  e  oito  foram  sujeitos  a  embolizac¸ão  da  artéria  esplénica  e/ou  esplenec-
tomia. Não  se  veriﬁcaram  casos  de  recidiva  hemorrágica  e  ocorreram  duas  mortes.  Os  doentes
sem alterac¸ões  da  enzimologia  hepática  foram  os  mais  propensos  a  apresentar  hemorragia
gastrointestinal  (87,5%  vs.  28,6%;  p  =  0,024).
Conclusões:  A  pancreatite  aguda  e  a  pancreatite  crónica  são  as  principais  causas  da  HTPS.
A hemorragia  gastrointestinal  é  a  manifestac¸ão  clínica  mais  relevante  e  os  doentes  sem
alterac¸ões da  enzimologia  hepática  parecem  apresentar  um  risco  superior  para  desenvolver
esta complicac¸ão.  O  tratamento  especíﬁco  raramente  é  necessário/realizado.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.

















Sinistral  portal  hypertension  (SPH)  is  also  known  as
splenoportal,  left-sided,  segmental,  regional,  localized,
compartmental  or  lineal  portal  hypertension.1,2 Its’  patho-
physiology  was  ﬁrst  outlined  by  Greenwald  and  Wasch  in
1939.3 It  is  a  rare  entity,  accounting  for  less  than  5%
of  all  patients  with  portal  hypertension,  and  results  from
splenic  vein  thrombosis  or  occlusion,  with  patent  extra-
hepatic  portal  vein.2,4--8 In  fact,  the  name  sinistral  portal
hypertension  is  a  misnomer  since  portal  pressure  is  usu-
ally  within  the  normal  range  in  these  cases.2,9,10 Patients’
liver  function  is  generally  unaffected  but  gastric  and/or
esophageal  varices  are  common  and  upper  gastrointestinal
bleeding  (UGIB)  might  be  a  potential  life-threatening  clinical
manifestation.2,5 However,  many  patients  are  asymptomatic
or  have  unspeciﬁc  abdominal  pain.  Pancreatic  inﬂam-
matory  or  neoplastic  diseases  are  the  main  causes  of
SPH.1,2,4--8,11--13UGIB  can  be  controlled  by  endoscopic  treatment  but
deﬁnitive  therapy  with  splenic  artery  embolization  or
splenectomy  can  be  deemed  necessary.  Treatment  of  asymp-




tThe  present  study  summarizes  clinical  presentation,  aeti-
logies  and  outcomes  in  a  cohort  of  consecutive  patients
iagnosed  with  SPH.  Potential  factors  associated  with
ncreased  UGIB  risk  were  also  determined.
.  Patients and methods
.1.  Patients  and  study  design
n  this  single-centre  study  the  medical  records  of  all  consec-
tive  patients  observed  in  a  Gastroenterology  Department
uring  2013--2014,  with  present  or  previous  diagnosis  of  SPH
ere  retrospectively  analyzed.  Diagnosis  of  SPH  was  based
n  criteria  previously  followed  by  Wang  et  al.:  presence
f  pancreatic  pathology;  clinical,  endoscopic  or  laboratory
vidence  of  portal  hypertension,  including  total  or  partial
cclusion  of  the  splenic  vein  and/or  splenomegaly;  exclusion
f  other  causes  of  portal  hypertension,  such  as  concomitant
ortal  vein  thrombosis  or  liver  cirrhosis. Patients  with  one
r  more  clinical,  imagiological  and  laboratory  modiﬁcations
uggestive  of  cirrhosis  were  immediately  excluded  from  fur-
her  analysis.  Clinical  manifestations,  associated  conditions,



































Table  1  Clinical  and  laboratory  characteristics.
Age,  years  (range)  59.6  ±  10.6
years  (42--77)
Male 17  (77.3%)
Aetiology
Chronic  pancreatitis  7  (31.8%)
Acute severe  pancreatitis 7  (31.8%)
Pancreatic  carcinoma 4  (18.2%)
Pancreatic  surgery 3  (13.7%)
AVM 1  (4.5%)
Pancreatic  ﬂuid  collections
Pseudocyst  7  (31.8%)
Walled-off  pancreatic  necrosis  2  (9.1%)
Splenomegaly  7  (31.8%)
Platelet  count  (median,  range)  ×  109/L 201.5  (66--437)
Thrombocytopenia  5  (22.7%)
Increased  aminotransferases,  GGT
and/or  alkaline  phosphatase
11  (50%)
Location  of  GI  varices
Gastric/fundal  (IGV1)  18  (81.9%)
Fundal  +  esophageal  (GOV  2)  2  (9.1%)
Esophageal  1  (4.5%)
Choledocojejunal  anastomosis  1  (4.5%)
AVM, arteriovenous malformation; GGT, gamma-glutamyl
transpeptidase; GI, gastrointestinal; GOV2, gastroesophageal






pancreatic  surgery,  all  due  to  malignant  neoplasms:  carci-
noma  of  the  Ampulla  of  Vater;  pancreatic  neuroendocrine
tumour;  pancreatic  metastasis  of  kidney  carcinoma.  Oneigure  1  Upper  gastrointestinal  endoscopy,  showing  fundal
arices after  treatment  with  cyanoacrylate.
aboratory  data,  diagnostic  evaluation,  survival  and  out-
omes  were  retrieved  from  medical  records.  Follow-up  was
ased  on  the  last  clinical  evaluation  in  the  patient’s  history
index  month  --  July  2015)  taking  in  account  the  ﬁrst  ima-
iological  examination  that  reported  alterations  compatible
ith  SPH.
.2.  Statistics
or  statistical  analysis  a  2-sample  t  test  or  a  Mann--Whitney
est  were  used  for  comparison  of  continuous  variables,
hereas  a  chi-square  test  or  a  2-sided  Fisher’s  exact  test
ere  used  to  compare  the  frequencies.  The  results  are
eported  for  signiﬁcant  variables  in  univariate  analysis  using
djusted  odds  ratios  (OR)  and  their  corresponding  95%  conﬁ-
ence  intervals  (CI).  The  statistical  software  package  SPSS
0.0  for  Windows  (SPSS,  Chicago,  IL,  USA)  was  used.
.3.  Ethical  considerations
he  study  adhered  to  all  principles  of  good  clinical  practice.
nformed  consent  was  obtained  from  all  patients  prior  to
ndoscopic  or  other  interventions  deemed  necessary.
. Results
n  this  2-year  period  a  total  of  22  patients  (male  --  17;  mean
ge  --  59.6  ±  10.6  years,  range  42--77  years)  with  SHP  were
ncluded  in  the  database.  Eight  patients  (36.4%)  had  present
r  past  history  of  UGIB  due  to  esophageal  and/or  gastric
arices  (Fig.  1).  There  were  no  records  of  gastrointestinal
leeding  from  other  locations  or  aetiologies.  The  remaining
4  patients  were  asymptomatic  or  had  unspeciﬁc  symptoms
uch  as  abdominal  pain.  Clinical  and  laboratory  characteris-
ics  are  resumed  in  Table  1.All  patients  have  no  liver  function  abnormalities.  Abdom-
nal  imaging  was  available  for  all  patients  (CT  scan  --  86.4%;
oppler  ultrasound  --  50%)  (Fig.  2).  In  the  imagiological  eval-
ation  there  were  no  liver  alterations  suggestive  of  cirrhosis
F
htype 1 (Sarin classiﬁcation).
r  abnormalities  in  the  portal  vein.  Endoscopic  ultrasound
as  also  performed  in  nine  patients  (40.9%)  with  conﬁrma-
ion  of  gastrointestinal  varices  in  all  of  them.
Eighteen  patients  had  partial  or  total  occlusion  of  spleen
enous  system  due  to  acute  pancreatitis,  chronic  pancreati-
is  or  pancreatic  neoplasms.  Three  patients  had  history  ofigure  2  CT  image  demonstrating  splenomegaly  and  splenic
ilum varices.

























































only  eight  patients  had  present  or  past  history  of  UGIB.8Figure  3  Angiographic  image  demonstrating  an  arteriovenous
malformation  involving  the  splenic  artery  and  veins.
patient  had  an  arteriovenous  malformation  without  occlu-
sion  of  splenic  vein.
Five  patients  with  UGIB  were  submitted  to  endoscopic
treatment  (cyanoacrylate  obliteration  of  fundal  varices
--  3;  esophageal  endoscopic  variceal  ligation  --  2).  The
two  patients  with  esophageal  variceal  bleeding  were  later
included  in  an  endoscopic  elective  ligation  programme.
Three  patients  with  UGIB  had  no  active  bleeding  in  the  ﬁrst
endoscopic  evaluation  and  a  watchful  waiting  strategy  was
adopted.  These  patients  had  no  immediate  rebleeding  and
were  later  referred  for  angiographic  or  surgical  interven-
tion.
Splenic  artery  embolization  was  performed  in  ﬁve
patients  (Fig.  3).  Two  of  them  were  afterwards  submitted  to
splenectomy.  Surgical  treatment  (splenectomy  with  or  with-
out  pancreatic  resection  or  pseudocyst  drainage)  was  also
performed  in  another  three  patients.  Angiographic  and/or
surgical  procedures  were  always  preceded  by  administration
of  pneumococcal,  meningococcal,  Haemophilus  inﬂuenza
type  B  and  inﬂuenza  vaccines.
Study  of  hereditary  thrombophilias  was  available  in  three
cases  and  it  was  negative  for  all  of  them.
Five  patients  (22.7%)  were  medicated  with  anticoagu-
lants  (low  molecular  weight  heparin  and/or  varfarin).  The
two  patients  with  walled-off  pancreatic  necrosis  were  sub-
mitted  to  endoscopic  drainage  and  necrosectomy.
Median  follow-up  time  was  24  months  (range  0--120
months).  There  were  no  cases  of  variceal  rebleeding  but  two
patients  died,  one  due  to  pancreatic  carcinoma  and  another
from  infectious  complications  not  related  with  SHP.
Levels  of  aminotransferases,  alkaline  phosphatase
and/or  gamma-glutamyl  transpeptidase  were  normal  in
87.5%  of  patients  with  UGIB,  comparatively  to  28.6%  of
patients  without  gastrointestinal  haemorrhage  (OR  17.50;
95%  CI  1.59--191.89;  p  =  0.024).  There  were  no  other  factors




hrombotic  occlusion  of  the  splenic  vein  is  generally  the
rimary  cause  of  SPH  and  pancreatic  diseases  are  the
ain  sources  of  such  thrombosis.2,5 This  occurs  because
he  splenic  vein  traverses  the  pancreatic  surface  and  the
nﬂammatory  or  neoplastic  pathologies  can  affect  this  ves-
el  by  a  contiguity  process.4,5,7,11--13 Other  causes  of  SHP
uch  as  iatrogenic  splenic  vein  injury  after  liver  transplan-
ation,  partial  gastrectomy,  inﬁltration  by  other  tumours,
etroperitoneal  ﬁbrosis,  abdominal/retroperitoneal  tuber-
ulosis,  spontaneous  splenic  vein  thrombosis,  perirenal
bscess,  splenic  lymphoma  with  splenic  vein  thrombosis,
ereditary  thrombophilias  and  idiopathic  splenic  vein  throm-
osis  associated  with  pregnancy  have  also  been  linked  with
PH  but,  these  etiological  factors  are  rare.2,8,15--23 In  our
eries,  pancreatitis  (acute  or  chronic)  and  pancreatic  neo-
lasms  accounted  for  81.8%  of  SHP  cases.  Three  patients  had
istory  of  pancreatic  surgery  but,  according  to  the  medi-
al  records,  SHP  was  not  present  before  surgery.  SHP  after
ancreatic  surgery  was  previously  documented  by  other
uthors.7 Splenic  vein  ligation  could  be  a  cause  of  iatro-
enic  SHP  but  we  were  not  able  to  conﬁrm  if  that  happened
n  these  three  patients.24 We  assume  that  anatomical  modiﬁ-
ations  after  surgery  were  responsible  for  SHP  development.
It  is  interesting  to  notice  that  one  patient  had  not  a
otal  occlusion  of  the  splenic  vein.  This  patient  presented
ith  massive  UGIB  due  to  a  fundal  varix  that  was  controlled
ith  cyanoacrylate.  The  imagiological  studies  revealed  an
VM  involving  the  splenic  artery  and  vein,  determining  a
ajor  overﬂow  in  the  splenic  vein  and  splenomegaly.  To
ur  knowledge  this  is  the  ﬁrst  case  of  SHP  reported  in
edical  literature  with  such  aetiology.  Physiopathologically
he  result  was  the  same  as  total  occlusion  of  splenic  vein,
ith  an  increased  pressure  in  the  splenic  venous  system,
hich  was  transmitted  through  the  anastomoses  between
he  splenic  vein  and  gastric  or  gastroepiploic  veins,  resulting
n  gastric  or  gastroesophageal  varices.  Regularly,  esophageal
arices  are  less  common  than  fundal  varices  because  the
ortal  venous  pressure  is  normal  and  blood  drainage  is
hrough  a  patent  coronary  vein.  Combined  esophageal  and
astric  varices  or  isolated  esophageal  varices  occur  only
hen  the  coronary  vein  drains  distal  to  the  obstruction
n  the  splenic  vein.7,8 All  our  patients  had  gastric  and/or
sophageal  varices  and  one,  with  previous  surgery,  also  had
holedocojejunal  varices  which  were  the  source  of  bleed-
ng.  According  to  the  literature  45--72%  of  patients  with
HP  present  with  UGIB  due  to  ruptured  varices  and  25--38%
ad  abdominal  pain.2,8,12 The  majority  of  our  patients  were
symptomatic  or  had  unspeciﬁc  abdominal  pain  and  less
han  40%  presented  UGIB.  In  another  retrospective  series
nly  15%  of  patients  with  splenic  vein  thrombosis  experi-
nced  variceal  bleeding.25 A  prospective  study  in  patients
ith  chronic  pancreatitis  revealed  that  only  8%  suffered
rom  splenic  vein  thrombosis,  the  majority  of  whom  did
ot  experience  any  form  of  symptomatic  GI  bleeding.26 In
 study  from  Koklu  et  al.,  involving  24  patients,  chronic
bdominal  pain  was  also  the  most  common  complaint  andSPH  is  often  associated  with  splenomegaly  and  normal
iver  function.5 In  our  series  only  seven  patients  had  a



































































































ases.  Some  authors  reported  that  splenomegaly  was  uni-
ersal  in  their  patients  with  SHP  but,  that  did  not  happen
n  reports  from  another  authors.5,7,8 Curiously,  50%  of  our
atients  had  minor  elevations  of  aminotransferases,  GGT
nd/or  alkaline  phosphatase  of  different  origins,  including
rug-related  and  non-alcoholic  fatty  liver  disease.  These
atients  had,  apparently,  a  lower  risk  of  UGIB  but  we  found
o  plausible  explanation  for  such  fact.  It  would  be  interest-
ng  to  see  if  such  ﬁnding  is  reproduced  in  series  of  SHP  from
nother  centres.
Management  of  SPH  involves  surgical  correction  of  the
nderlying  causes,  such  as  pancreatic  neoplasms  or  cysts,
ombined  with  splenectomy,  to  diminish  the  arterial  inﬂow
nto  the  left  portal  system.6,9,14 More  recently,  splenic
rtery  embolization  was  also  advocated  and  it  can  be  use-
ul  even  before  laparoscopic  splenectomy  in  patients  with
plenomegaly.9,27--29 It  can  be  a  life-saving  procedure  in
atients  with  massive  UGIB  after  failure  of  endoscopic
rocedures.22 Endovascular  procedures  might  be  associated
ith  serious  complications  such  as  partial  gastric  and/or
ancreatic  infarctions,  splenic  rupture,  acute  pancreatitis,
leural  effusion,  lung  atelectasis,  sepsis  and  the  so-called
‘post-infarction  syndrome’’,  represented  by  abdominal
ain,  leukocytosis  and  fever  as  well  as  splenic  abscesses.28,29
ortunately,  we  registered  no  complications  in  our  patients.
ll  of  them  were  previously  vaccinated  and  received  antibi-
tic  coverage  during  the  procedure,  as  stated  in  medical
iterature.29,30
Surgical  intervention  was  also  advocated  in  the  past  for
symptomatic  patients  but,  now  it  is  not  consensual  and
 conservative  management  might  be  acceptable  in  such
ircumstances.2,5,9,14
We  identiﬁed  ﬁve  patients  with  hypersplenism.  Three
f  them  were  submitted  to  splenic  artery  embolization
nd/or  splenectomy.  The  other  two  had  esophageal  varices,
menable  to  endoscopic  ligation,  and  the  platelet  count  was
nly  slightly  diminished.  Previous  reports  had  also  identiﬁed
 high  success  rate  in  variceal  eradication  with  the  simple
se  of  endoscopic  therapies.31
From  the  eight  patients  with  UGIB  four  were  proposed  for
peciﬁc  angiographic  or  surgical  intervention,  two  were  the
nes  with  esophageal  varices  and  another  two  had  history
f  recent  pancreatic  surgery  and  a  conservative  approach
as  decided  after  endoscopic  control  of  bleeding.  Curiously,
here  were  no  cases  of  rebleeding  or  new  bleedings  dur-
ng  follow-up.  Koklu  et  al.  also  found  no  cases  of  recurrent
leeding  in  six  patients  whom  presented  with  gastroin-
estinal  bleeding  on  admission  and  only  one  of  them  was
ubmitted  to  splenectomy.8 Given  these  results  we  advo-
ate  a  cautious  approach  to  patients  with  SHP,  even  if
ymptomatic,  since  the  beneﬁt  of  angiographic  or  surgical
nterventions  can  be  outweighed  by  its’  risks.
Anticoagulation  for  patients  with  accidentally  detected
hrombosis  of  veins  from  the  splanchnic  system  is  not  con-
ensual  and  gastrointestinal  bleeding  risk  must  be  taken  into
ccount.32 There  is  limited  information  about  anticoagula-
ion  in  patients  with  SHP  and  this  explains  why  only  a  few
f  our  patients  were  under  oral  or  parenteral  anticoagula-
ion.  Theoretically  anticoagulation  should  be  instituted  in
ll  patients  with  inﬂammatory  or  neoplastic  vein  thrombosis
ut,  in  patients  with  fundal  varices  it  is  difﬁcult  to  estab-
ish  bleeding  risk.  Probably,  anticoagulation  in  such  casesA.  Fernandes  et  al.
hould  only  be  started  after  cyanoacrylate  embolization.
owever,  this  procedure  is  not  risk-free  and  it  is  difﬁcult
o  assume  such  approach  in  asymptomatic  patients.  Further
tudies  are  needed  in  this  area  of  knowledge.  It  is  also  inter-
sting  to  notice  that  there  are  few  cases  of  SHP  related  with
oagulation  disorders.
Our  study  has  some  important  limitations  that  must
e  highlighted:  it  is  a  retrospective  analysis  that  included
atients  with  recent  and  previous  diagnosis  of  SHP  and  so,
here  could  be  some  bias  of  inclusion  but,  given  the  few
umber  of  patients  diagnosed  with  SHP  each  year  it  will  be
ifﬁcult  to  perform  a  prospective  study;  there  is  no  real  data
bout  the  annual  incidence  of  SHP  in  our  series;  it  is  not  rep-
esentative  of  an  all  region  since  only  patients  followed  in
he  Gastroenterology  Department  were  included;  it  would
e  interesting  to  have  data  about  hereditary  thrombophilias
n  all  patients.
. Conclusions
HP  is  generally  associated  with  pancreatic  disorders  and
n  our  series  acute  or  chronic  pancreatitis  were  the  main
etiologies.  Most  patients  are  asymptomatic  and  UGIB  is  the
ain  clinical  manifestation.  Surgical  and/or  endovascular
reatment  is  advocated  for  patients  with  UGIB  and/or  hyper-
plenism  but  a  conservative  approach  should  be  adopted  in
he  remainder.  Anticoagulation  is  not  consensual  and  must
e  considered  in  a case-by-case  scenario.
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